Skip to main content
ConductScienceScienceDex
NIH funding notice RFA-TR-22-011

Emergency Awards: HEAL Initiative-Early-Stage Discovery of New Pain and Opioid Use Disorder Targets Within the Understudied Druggable Proteome (R21 Clinical Trial Not Allowed)

Closed on April 17, 2023.

Posted
January 20, 2022
Close date
April 17, 2023
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.

Past awards
8
8 new
Median first-year cost
$432,063
$3,122,494 in all
Institutions
8
8 contact PIs

Awards by fiscal year

Fiscal years 2014 to 2026.

Most frequent institutions

  1. COLUMBIA UNIVERSITY HEALTH SCIENCES1
  2. CREIGHTON UNIVERSITY1
  3. INDIANA UNIVERSITY INDIANAPOLIS1
  4. NEW YORK UNIVERSITY SCHOOL OF MEDICINE1
  5. UNIVERSITY OF ILLINOIS AT CHICAGO1

and 3 other institutions

Most frequent study sections

  1. Special Emphasis Panel (ZTR1 DPI-1 (01))5
  2. Special Emphasis Panel (ZTR1 DPI-7 (01))3
8 awards under RFA-TR-22-011 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
FY2023DISCOVERY OF NOVEL TARGETS FOR POST-TRAUMATIC HEADACHE1R21NS132565-01Cao, YuqingWASHINGTON UNIVERSITY, MOFirst-year cost $428,250Study section ZTR1
FY2023Exploration of MBD1 as a therapeutic target for chronic pain1R21TR004701-01Stone, Laura SUNIVERSITY OF MINNESOTA, MNFirst-year cost $419,129Study section ZTR1
FY2023Structure-Function and Signaling of Glutamate Delta 1 in Pain Mechanism1R21NS132590-01Dravid, Shashank ManoharCREIGHTON UNIVERSITY, NEFirst-year cost $44,586Study section ZTR1
FY2022Discovery of novel openers of the understudied human drug target Kir6.11R21TR004333-01Cardozo, Timothy JNEW YORK UNIVERSITY SCHOOL OF MEDICINE, NYFirst-year cost $466,125Study section ZTR1
FY2022Erythrocyte Autophagy Proteins as Potential Non-opioid Novel Targets for Pain in Sickle Cell Disease1R21AT012304-01Ramasamy, JagadeeshUNIVERSITY OF ILLINOIS AT CHICAGO, ILFirst-year cost $455,195Study section ZTR1
FY2022Novel genetically-encoded inhibitors to probe functional logic of Cav-beta molecular diversity1R21NS130409-01Colecraft, Henry M.COLUMBIA UNIVERSITY HEALTH SCIENCES, NYFirst-year cost $449,834Study section ZTR1
FY2022The role of a lysosomal mechano-sensitive ion channel in pain1R21NS130417-01Fehrenbacher, Jill CSheets, Patrick LINDIANA UNIVERSITY INDIANAPOLIS, INFirst-year cost $435,875Study section ZTR1
FY2022G alpha Z subunit as a potential therapeutic target to modulate mu opioid receptor pharmacology1R21DA057500-01Bidlack, Jean MUNIVERSITY OF ROCHESTER, NYFirst-year cost $423,500Study section ZTR1
Newest fiscal year first, then first-year cost.

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-17-0.3.6. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for departments

Open NIH notices that fit your faculty

See which open NIH funding notices fit each faculty member's CV, why each fits, and who won before.

RFA-TR-22-011: Emergency Awards: HEAL Initiative-Early-Stage Discovery of New Pain and Opioid Use Disorder Targets Within the Understudied Druggable Proteome (R21 Clinical Trial Not Allowed) | ConductScience ScienceDex